← Back to blog
DividendJuly 1, 2026

Dividend Win Wednesday: Semiconductor Capital at 85% Off and Insiders Buying Energy

Top 5 Pixie Picks

Only Pro and Free Trial readers get meta-analysis of the top 5 ranked Dividend stocks.

Sign in

6. Biogen Inc. (BIIB)

Dividend yield: n/a | Payout ratio: 0.0% | 52w drawdown: -3.7% (near high)

Biogen trades at a 6.2% free cash flow yield with 75.7% gross margins and $84.2 million in net insider purchases over six months, the largest dollar accumulation in this week's screen. The company sits 3.7% above its 52-week high (near-high zone) at a 23.0 forward multiple while analysts project modest 2.7% upside to $219.44 from the current $213.66 price.

Three insiders filed Form 4 purchases on June 11: Mantas Jesus B, Minor Lloyd, and Freire Maria C, with insider buy transactions representing 50.4% of all activity versus 2.0% sells. Samsung Bioepis relaunched BYOOVIZ (ranibizumab-nuna) in the U.S. in partnership with Harrow on June 30, expanding the biosimilar franchise while Biogen maintains a 6.4× interest coverage ratio and 0.64× net debt to EBITDA.

Biogen pays no dividend despite a 70.2% ROIC, choosing instead to deploy capital into pipeline investments and share repurchases; the lack of income return removes a key risk buffer if the stock corrects from near-high levels. Next earnings land July 29 with $2.09 EPS expected on $2.4 billion revenue; consensus negative $7.16 EPS for the August 6 period reflects accounting treatment, not operational cash flow.

7. Exxon Mobil Corporation (XOM)

Dividend yield: 3.0% | Payout ratio: 59.2% | 52w drawdown: 23.2%

Exxon posts a 4.2% free cash flow yield and 11.1% ROIC at a 22.8 forward multiple, trading 23% below its 52-week high while maintaining a 69.4× interest coverage ratio and 0.70× net debt to EBITDA. The company's shareholder yield of 3.3% (dividend plus buybacks) underpins capital return even as revenue declined 4.5% year-over-year and the five-year dividend growth rate turned negative at -10.0%, reflecting the 2020 pandemic cut.

Insiders purchased $5.04 million net over six months, adding 32,250 shares with buy transactions at 1.5% versus 0.6% sells. Sable Offshore raised $300 million via notes and a share offering to repay an Exxon loan on June 30, a downstream financing event that reduces counterparty exposure while Exxon redirects capital to upstream and chemicals.

Analysts project $169.91 upside (25.3% above the $135.57 price) contingent on a recovery in global refining margins and crude price stabilization; the integrated model provides ballast but limits torque to upstream-only plays. Next earnings hit July 31 with $3.73 EPS expected on $101.5 billion revenue.

8. Gilead Sciences, Inc. (GILD)

Dividend yield: 2.6% | Payout ratio: 47.9% | 52w drawdown: 20.7%

Gilead delivers a 6.1% free cash flow yield with 78.8% gross margins and 24.4% ROIC, trading 21% below its 52-week high at a 17.0 forward multiple while analysts project $157.83 upside (26.5% above the $124.78 price). The company grew revenue 2.4% year-over-year and maintains a 10.6× interest coverage ratio with 0.84× net debt to EBITDA, supporting a 47.9% payout ratio on a 1.2% shareholder yield.

Insiders added $6.14 million net over six months, purchasing 283,785 shares with Form 4 filings from Dickinson Andrew D (June 11 and June 16) and Mercier Johanna (June 16); buy transactions represented 53.0% of activity versus 30.1% sells. The FDA approved Trodelvy for triple-negative breast cancer in June, expanding the oncology franchise and reinforcing the 14.7% normalized 10-year earnings yield.

Consensus projects negative $7.16 EPS for the August 6 earnings date, an accounting artifact from acquisition charges; core operations remain cash-generative, but the headline figure will distort media coverage. Revenue estimate of $7.4 billion assumes continued HIV and oncology momentum without material pipeline setbacks.


What to Watch

  • July 21 (Novartis), July 23 (Newmont), July 29 (Biogen, KLA), July 30 (KLA), July 31 (Exxon), August 4 (EOG), August 6 (ConocoPhillips, Gilead): Eight earnings releases across energy, metals, pharma, and biotech will test whether Q2 cash flow supports current payout ratios or triggers analyst estimate cuts.

  • July CPI and FOMC minutes (mid-month): If inflation prints softer, the 10Y Treasury yield could compress further, widening yield spreads for high-FCF energy and pharma names and potentially pulling capital back into dividend stocks from money-market funds.

  • Samsung/SK Hynix capital deployment updates (ongoing): The $1.3 trillion Korea semiconductor build-out announced June 30 is a multi-year tailwind for KLA; watch for equipment order announcements or fab construction timelines that confirm 2026-2027 revenue visibility.

  • Gold price action through Q3: Newmont's 31% drawdown and 53% analyst upside assume gold stabilizes after its worst quarterly selloff in 13 years; a further leg down breaks the thesis, while a rebound to $2,100+ per ounce could accelerate the stock 20%+ in weeks.


Go Deeper

The dividend screener ranks companies by free cash flow yield, payout sustainability, insider conviction, and drawdown opportunity.
Check out the full screener →

Pro-only analytics

Named tickers from this article open in the app with Pro or an active trial.

Sign in

Stock Pixie Pro

See the full dividend screen — every pick, every metric, every day.

The app shows up to 10 rows on Free; the top 5 by Pixie rank keep ticker, name, and recent close private. Posts may name the top 5 for context. Pro and trial show every row on the screener, full identifiers, and the rest of Pro.

Start your free trial

About the Stock Pixie Score

The Stock Pixie Score is a 0–10 composite that measures how well a stock matches the criteria for that screen. Scores reflect the strength of quantitative signals across valuation, quality, and trend factors weighted for the specific screener. A higher score means stronger alignment; above 8 indicates the algorithm finds the setup compelling across most of the metrics it tracks. It is a filter, not a forecast.

The Fine Print

Stock Pixie is not a registered investment adviser and does not offer financial advice. It is a stock screening platform that scores and ranks stocks using quantitative signals. You are responsible for your own research and investment decisions. Past performance does not guarantee future results.